Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, multicentrická studie, práce podpořená grantem
- Klíčová slova
- Multiple myeloma, cytogenetic abnormalities, prognosis, thalidomide,
- MeSH
- analýza přežití MeSH
- chromozomální delece * MeSH
- duplikace chromozomů * MeSH
- hybridizace in situ fluorescenční MeSH
- incidence MeSH
- lidé MeSH
- lidské chromozomy, pár 1 MeSH
- lidské chromozomy, pár 14 MeSH
- lidské chromozomy, pár 17 MeSH
- lidské chromozomy, pár 4 MeSH
- mnohočetný myelom epidemiologie genetika mortalita MeSH
- prognóza MeSH
- retrospektivní studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- translokace genetická * MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Polsko epidemiologie MeSH
The study aimed to assess prognostic significance of del(13q14), del(17p13), t(4;14)(p16;q32), and amp(1q21) in newly diagnosed myeloma patients treated mostly with thalidomide-based therapies. All genetic abnormalities except del(13q14) were independent prognostic factors associated with shortened progression-free survival (PFS) and overall survival (OS). Patients with no abnormalities, one abnormality, and ≥2 abnormalities had a median PFS of 41.8, 17.0, and 10.0 months, respectively; a median OS was not reached, 48.0 and 23.3 months, respectively. According to the presence of amp(1q21), t(4;14)(p16;q32), and del(17p13) and the International Staging System (ISS), we stratified patients into low-risk, intermediate-risk and high-risk groups. A median PFS was 52.9, 25.6, and 10.0 months, respectively; a median OS was not reached, 64.0 and 25.0 months, respectively. In conclusion, our study confirmed the prognostic value of cytogenetic changes and showed that prognostic models based on ISS and cytogenetic studies should include not only del(17p13) and t(4;14)(p16;q32), but also amp(1q21).
b Department of Experimental Hematooncology Medical University of Lublin Lublin Poland
c University Hospital Ostrava and Faculty of Medicine University of Ostrava Ostrava Czech Republic
Department of Ergonomics Faculty of Management Lublin University of Technology Lublin Poland
Department of Hematology St John's Cancer Center Lublin Poland
h Department of Hematology Jagiellonian University Medical College Cracow Poland
i Department of Biochemical Diagnostics Medical University of Lublin Lublin Poland
Citace poskytuje Crossref.org
